Ascentage Pharma (6855.HK) today announced that its seven clinical abstracts selected by the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, of which six were selected for presentations and one was selected for publication-only, have been published on the ASCO’s website. These abstracts are related to seven clinical studies of the company’s five novel drug candidates, including the third-generation tyrosine kinase inhibitor (TKI), olverembatinib (HQP1351); the Bcl-2 inhibitor, lisaftoclax (APG-2575); the MDM-p53 inhibitor, alrizomadlin (APG-115); the ALK/ROS1/FAK inhibitor, APG-2449; and the dual Bcl-2/Bcl-xL inhibitor, pelcitoclax (APG-1252).The ASCO Annual Meeting showcases cutting-edge research in clinical oncology, state-of-the-art advancements in cancer therapies, and is the world’s most influential scientific gathering of the oncology community. This year’s ASCO Annual Meeting will take place both online and in-person (McCormick Place; Chica
………………………………
